Sex differences in the prognosis of nonsustained ventricular tachycardia detected on Holter recording.

Background: Nonsustained ventricular tachycardia (NSVT) is a common finding during cardiac evaluation and has been linked to increased mortality. While some studies report a sex difference, most data stem from research cohorts.

Objective: This study aimed to assess the prognostic significance of NSVT in a real-life outpatient clinic, focusing on sex differences in mortality.

Efficacy and Safety of Anthocyanin-Rich Extract in Patients with Ulcerative Colitis: A Randomized Controlled Trial.

Bilberries are effective in inducing clinical, endoscopic, and biochemical improvement in ulcerative colitis (UC) patients. The aim of this study was to investigate the efficacy of anthocyanin-rich extract (ACRE), the bioactive ingredient of bilberries, in a controlled clinical trial in moderate-to-severe UC. A multi-center, randomized, placebo-controlled, double-blind study with a parallel group was conducted.

Atmospheric Chemistry of ()- and ()-CFCFCH═CHCFCF (HFO-153-10mczz): Kinetics and Mechanisms of the Reactions with Cl Atoms, OH Radicals, and O.

Smog chamber experiments were conducted to establish the atmospheric chemistry of ()- and ()-CFCFCH═CHCFCF. Kinetics of the reactions of the two compounds with Cl atoms and OH radicals were measured using relative rate techniques, giving (Cl + ()-CFCFCH═CHCFCF) = (5.63 ± 0.

Metabolomics for enhanced clinical understanding of inflammatory bowel disease.

Metabolomics is an emerging field involving the systematic identification and quantification of numerous metabolites in biological samples. Precision medicine applies multiomics systems biology to individual patients for reliable diagnostic classification, disease monitoring, and treatment. Multiomics systems biology encompasses genomics, transcriptomics, proteomics, epigenomics, and metabolomics.

Immunogenicity of Therapeutic Antibodies Used for Inflammatory Bowel Disease: Treatment and Clinical Considerations.

The introduction of tumor necrosis factor inhibitors has led to a paradigm shift in the management of inflammatory bowel disease (IBD). The subsequent introduction of both anti-integrins and cytokine blockers has since expanded the biologic armamentarium. However, immunogenicity, defined as the production of anti-drug antibodies (ADAs) to the prescribed biopharmaceutical, means a significant fraction of patients exposed to biologic agents will experience a secondary loss of response to one or more of the drugs.